The combined effect of amyloid-beta and tau biomarkers on brain atrophy in dementia with Lewy bodies
Por:
Abdelnour, C, Ferreira, D, Oppedal, K, Cavallin, L, Bousiges, O, Wahlund, LO, Hort, J, Nedelska, Z, Padovani, A, Pilotto, A, Bonanni, L, Kramberger, MG, Boada, M, Westman, E, Pagonabarraga, J, Kulisevsky, J, Blanc, F, Aarsland, D
Publicada:
1 ene 2020
Resumen:
Background: Alzheimer's disease (AD)-related pathology is frequently found in patients with dementia with Lewy bodies (DLB). However, it is unknown how amyloid-beta and tau-related pathologies influence neurodegeneration in DLB. Understanding the mechanisms underlying brain atrophy in DLB can improve our knowledge about disease progression, differential diagnosis, drug development and testing of anti-amyloid and anti-tau therapies in DLB.
Objectives: We aimed at investigating the combined effect of CSF amyloid-beta 42, phosphorylated tau and total tau on regional brain atrophy in DLB in the European DLB (E-DLB) cohort.
Methods: 86 probable DLB patients from the E-DLB cohort with CSF and MRI data were included. Random forest was used to analyze the association of CSF biomarkers (predictors) with visual rating scales for medial temporal lobe atrophy (MTA), posterior atrophy (PA) and global cortical atrophy scale-frontal subscale (GCA-F) (outcomes), including age, sex, education and disease duration as extra predictors.
Results: DLB patients with abnormal MTA scores had abnormal CSF A beta 42, shorter disease duration and older age. DLB patients with abnormal PA scores had abnormal levels of CSF A beta 42 and p-tau, older age, lower education and shorter disease duration. Abnormal GCA-F scores were associated with lower education, male sex, and older age, but not with any AD-related CSF biomarker.
Conclusions: This study shows preliminary data on the potential combined effect of amyloid-beta and tau-related pathologies on the integrity of posterior brain cortices in DLB patients, whereas only amyloid-beta seems to be related to MTA. Future availability of a-synuclein biomarkers will help us to understand the effect of a-synuclein and AD-related pathologies on brain integrity in DLB.
Filiaciones:
Abdelnour, C:
Univ Int Catalunya Barcelona, Inst Catala Neurociencies Aplicades, Ctr Invest Red Enfermedades Neurodegenerat CIBERN, Res Ctr & Memory Clin,Fundacio ACE, Barcelona, Spain
Univ Autonoma Barcelona, Dept Med, Barcelona, Spain
Ferreira, D:
Karolinska Inst, Div Clin Geriatr, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden
Oppedal, K:
Stavanger Univ Hosp, Ctr Age Related Med, Stavanger, Norway
Stavanger Univ Hosp, Dept Radiol, Stavanger, Norway
Univ Stavanger, Dept Elect Engn & Comp Sci, Stavanger, Norway
Cavallin, L:
Karolinska Inst, Dept Neurosci, Stockholm, Sweden
Karolinska Univ Hosp, Dept Radiol, Stockholm, Sweden
Bousiges, O:
Hop Univ Strasbourg, Lab Biochimie & Biol Mol, Strasbourg, France
CNRS, UMR7364, Lab Neurosci Cognit & Adaptat LNCA, Strasbourg, France
Wahlund, LO:
Karolinska Inst, Div Clin Geriatr, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden
Hort, J:
Charles Univ Prague, Dept Neurol, Med Fac 2, Prague, Czech Republic
Motol Univ Hosp, Prague, Czech Republic
Int Clin Res Ctr, Brno, Czech Republic
Nedelska, Z:
Charles Univ Prague, Dept Neurol, Med Fac 2, Prague, Czech Republic
Motol Univ Hosp, Prague, Czech Republic
Int Clin Res Ctr, Brno, Czech Republic
Padovani, A:
Univ Brescia, Dept Clin & Expt Sci, Neurol Unit, Brescia, Italy
Pilotto, A:
Univ Brescia, Dept Clin & Expt Sci, Neurol Unit, Brescia, Italy
Bonanni, L:
Univ G dAnnunzio, Dept Neurosci Imaging & Clin Sci, Chieti, Italy
Univ G dAnnunzio, CESI, Chieti, Italy
Kramberger, MG:
Univ Ljubljana, Univ Med Ctr Ljubljana, Med Fac, Dept Neurol, Ljubljana, Slovenia
Boada, M:
Univ Int Catalunya Barcelona, Inst Catala Neurociencies Aplicades, Ctr Invest Red Enfermedades Neurodegenerat CIBERN, Res Ctr & Memory Clin,Fundacio ACE, Barcelona, Spain
Westman, E:
Karolinska Inst, Div Clin Geriatr, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden
Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Neuroimaging, Ctr Neuroimaging Sci, London, England
Pagonabarraga, J:
Hosp Santa Creu & Sant Pau, Neurol Dept, Ctr Invest Red Enfermedades Neurodegenerat CIBERN, Movement Disorders Unit,Biomed Res Inst IIB St Pa, Barcelona, Spain
Kulisevsky, J:
Hosp Santa Creu & Sant Pau, Neurol Dept, Ctr Invest Red Enfermedades Neurodegenerat CIBERN, Movement Disorders Unit,Biomed Res Inst IIB St Pa, Barcelona, Spain
Blanc, F:
Hop Univ Strasbourg, CMRR Ctr Memoire Ressource & Rech, Hop Jour, Pole Geriatrie, Strasbourg, France
CNRS, UMR 7357, Lab ICube, Strasbourg, France
Equipe IMIS Neurocrypto, FMTS Federat Med Translat Strasbourg, Strasbourg, France
Aarsland, D:
Stavanger Univ Hosp, Ctr Age Related Med, Stavanger, Norway
Stavanger Univ Hosp, Dept Radiol, Stavanger, Norway
Kings Coll London, Inst Psychiat Psychol & Neurosci, London, England
Gold, Green Published
|